Company / PP&E (Net)
CRISPR Therapeutics AG PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$115.9M
FY2025
5-year range
$115.9M / $163.6M
FY2021-FY2025
Trend
-13.6%
vs FY2024
Sector context
#40 of 195
Health Care
What the data says
CRISPR Therapeutics AG's pp&e (net) of $116M is higher than 79% of companies in the Health Care sector (FY2025). PP&E (Net) has declined for 3 consecutive years, from $164M in FY2022 to $116M in FY2025.
Based on SEC 10-K filings.
$116M in FY2025 with a 5-year CAGR of +22.4%. Top quartile in the Health Care sector.
Declined from $152M to $116M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -10.9%
- 5-Year CAGR
- +22.4%
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 195This company $115.9M Sector average $770.1M
▼
-85.0% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of +22.4%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 13.6% year-over-year.
- Ranks #40 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $115.9M | -13.6% |
| FY2024 | $134.1M | -11.7% |
| FY2023 | $151.9M | -7.1% |
| FY2022 | $163.6M | +18.9% |
| FY2021 | $137.6M | +226.3% |
| FY2020 | $42.2M | +34.6% |
| FY2019 | $31.3M | +69.4% |
| FY2018 | $18.5M | -1.9% |
| FY2017 | $18.9M | -10.3% |
| FY2016 | $21.0M | +1483.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026